Author: Xue, Wenhua; Yan, Dan; Kan, Quancheng
Title: Interleukin-35 as an Emerging Player in Tumor Microenvironment Document date: 2019_5_12
ID: zxrgkhmr_16
Snippet: Despite the growing evidence that directly implicates IL-35 for immune evasion of tumor cells due to its inhibitory actions, it is interesting to notice that majority of IL-35 is released from Treg cells. These Treg cells are recruited to tumor sites to avoid any miscalculation, the result of which is less number of CD4 + T cells and CD8 + CTLs in TME to combat cancer. Intriguingly, depletion of Tregs cells exerted similar effects on cancer devel.....
Document: Despite the growing evidence that directly implicates IL-35 for immune evasion of tumor cells due to its inhibitory actions, it is interesting to notice that majority of IL-35 is released from Treg cells. These Treg cells are recruited to tumor sites to avoid any miscalculation, the result of which is less number of CD4 + T cells and CD8 + CTLs in TME to combat cancer. Intriguingly, depletion of Tregs cells exerted similar effects on cancer development as IL-35 when studied alone [80] . Correspondingly, inhibition of mere suppressive signaling from Treg cells devoid of depletion led to better treatment outcomes [81, 82] . Likewise, blockade of Treg cells steered the reversal of CD8+ T cells exhaustion [83] . Increased Treg cells population is also seen in breast cancer patients [66] . Hence it may be plausible to argue that the suppressive action of Treg on T cell growth corresponds with IL-35 actions on the latter. This obviously confirms Treg cells as major producers of IL-35 as manipulation of either of them led to identical findings. Therefore, targeting IL-35 for tumor suppression can also be a viable option. One of the verification is performed by Meghan et al. who introduced EBI3 monoclonal antibody (mAb) that neutralizes IL-35 specifically but does not affect Tregs cells. Study findings manifested that neutralization of IL-35 resulted in improved tumor control in Wild-type C57BL/6 mice as compared to control mice [84] . An unorthodox study in this context is reported by Nicholl MB et al. which although described the role IL-35 in pancreatic cancers but found, rather surprisingly, that it was not expressed by Treg cells but expression found in epithelial derived pancreatic cancer (PCAN) cells [85] . In addition, cytokineinduced killer (CIK) cells are a heterogeneous cells population expressing cell markers for both T cells and natural killer cells and launch a robust attack against cancer cells [86] . CIK have well reported advantages in hematological malignancies and solid tumors in the past [87] [88] [89] . Studies also report the inverse relationship in number and function between Treg cells and CIK, understandably through release of inhibitory cytokines by former [90, 91] . Alternatively it is also documented that dendritic cells co-cultured with CIK led to suppression of Treg cells and its inhibitory cytokines [92] [93] [94] . Interestingly, Ying Pan and colleagues showed that Tregs cells and IL-35 concomitantly increased in a time-dependent manner during the generation of CIK cells as compared to DC-CIK co-cuture, which notably suspended the expression of Treg cells and IL-35 [95] .
Search related documents:
Co phrase search for related documents- breast cancer patient and cancer development: 1, 2, 3
- breast cancer patient and cancer patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68
- breast cancer patient and cell growth: 1
- breast cancer patient and immune evasion: 1
- breast cancer patient and inverse relationship: 1
- breast cancer patient and monoclonal antibody: 1
- breast cancer patient and pancreatic cancer: 1, 2
- breast cancer patient and tumor cell: 1, 2, 3
- breast cancer patient and tumor site: 1
Co phrase search for related documents, hyperlinks ordered by date